In the six-month follow-up, children in both groups who stopped treatment increased BMI and gained weight, the study found. The trial has been extended to include more treatment and follow up, with results expected in 2027. Fox receives research funding from Novo Nordisk and drugmaker...
Drugs designed to aid weight loss have become popular in recent months, and while the best known of them is probably Ozempic, there's also Wegovy and Saxenda. Now another drug called Mounjaro has been added to the race, and although it has not yet received FDA approval, but the approval ...
While the supply squeeze on Wegovy has “negatively impacted” prescription trends for that med, as expected, Saxenda trends “have picked up and are now at all-time high levels,” Novo’s North American lead Doug Langa said on Wednesday's investor call. Related Novo Nordisk, ...
Wegovy has set a new standard for obesity treatment, demonstrating an average weight loss of 15 percent, far surpassing the 8-9 percent weight loss seen with previous obesity medications. However, as interest in the drug has grown, its value has been tarnished by concerns about side effects an...
Because losing at least 5% of fasting body weight through lifestyle intervention during the 4- to 12-week run-in was a condition for their continued participation in the randomized treatment period, the results may not reflect those expected in the general population. Table 6 presents the ...